Welcome to LookChem.com Sign In|Join Free

CAS

  • or

101001-62-1

Post Buying Request

101001-62-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

101001-62-1 Usage

Description

A pyrrole derivative with a five-membered aromatic heterocycle and a nitrogen atom at position 1

Appearance

Colorless to light yellow liquid with a faint odor

Solubility

Insoluble in water

Uses

Intermediate in the synthesis of pharmaceutical and agricultural compounds, research and development for creating new chemical entities with potential biological activity, studied for potential antimicrobial and anticancer properties.

Check Digit Verification of cas no

The CAS Registry Mumber 101001-62-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,0,0 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 101001-62:
(8*1)+(7*0)+(6*1)+(5*0)+(4*0)+(3*1)+(2*6)+(1*2)=31
31 % 10 = 1
So 101001-62-1 is a valid CAS Registry Number.

101001-62-1Upstream product

101001-62-1Downstream Products

101001-62-1Relevant articles and documents

Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis

Kawahata, Wataru,Asami, Tokiko,Kiyoi, Takao,Irie, Takayuki,Taniguchi, Haruka,Asamitsu, Yuko,Inoue, Tomoko,Miyake, Takahiro,Sawa, Masaaki

supporting information, p. 8917 - 8933 (2018/10/09)

Bruton's tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, 4b. With significant efficacy in models in vivo and good ADME and safety profiles, 4b was advanced into preclinical studies.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 101001-62-1